TuHURA Q2 2026: cash $1.0M, R&D up to $6.6M, $50M credit facility extends runway to 2028

TuHURA Biosciences, Inc./NV

Cash and equivalents $1.0M at June 30, 2026; $5.7M drawn on $50M Parkview credit facility to date.
R&D expenses $6.6M in Q2 2026 vs $4.9M in Q2 2025; G&A $2.1M vs $1.9M.
Net operating cash outflow -$13.0M for H1 2026 vs -$10.9M in H1 2025; financing inflows $10.6M.
Filed IND for TBS-2025 VISTA antibody in AML; expect Phase 1b/2 initiation 2H 2026 and orphan drug designations.
$50M credit facility from largest shareholder at 12% interest, maturity 2031, extends cash runway into 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.